The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of immune checkpoint inhibitors (ICI) treatment in special populations of metastatic renal cell carcinoma (mRCC).
 
Daniel Vilarim Araujo
Honoraria - BMS Brazil; Libbs
 
Eoghan Ruadh Malone
No Relationships to Disclose
 
Adrian G. Sacher
Honoraria - AstraZeneca; Genentech/Roche; Merck; Pfizer
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer
Travel, Accommodations, Expenses - AstraZeneca; Genentech/Roche; Gritstone Bio; Pfizer
 
Nazanin Fallah-Rad
Honoraria - Bayer; Ipsen
Consulting or Advisory Role - Pfizer
Travel, Accommodations, Expenses - Nektar
 
Srikala S. Sridhar
Consulting or Advisory Role - Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Research Funding - Bayer (Inst); Janssen (Inst)
 
Aaron Richard Hansen
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline/Novartis; Merck; Pfizer
Consulting or Advisory Role - Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Genentech/Roche; GlaxoSmithKline; Merck; Novartis
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst)